000 05114nam a22003855i 4500
001 293156
003 MX-SnUAN
005 20160429155055.0
007 cr nn 008mamaa
008 150903s2006 au | o |||| 0|eng d
020 _a9783211333280
_99783211333280
024 7 _a10.1007/9783211333280
_2doi
035 _avtls000345410
039 9 _a201509030412
_bVLOAD
_c201405050320
_dVLOAD
_y201402061335
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC346-429.2
100 1 _aParvez, H.
_eeditor.
_9325528
245 1 0 _aOxidative Stress and Neuroprotection /
_cedited by H. Parvez, P. Riederer.
264 1 _aVienna :
_bSpringer Vienna,
_c2006.
300 _axiv, 264 páginas 72 ilustraciones
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aJournal of Neural Transmission. Supplementa ;
_v71
500 _aSpringer eBooks
505 0 _aLevodopa in the treatment of Parkinson’s disease -- Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole -- The DONPAD-study — Treatment of dementia in patients with Parkinson’s disease with donepezil -- PD-related psychosis: pathophysiology with therapeutical strategies -- Antioxidant capacity in postmortem brain tissues of Parkinson’s and Alzheimer’s diseases -- Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines — implications for the CNS -- Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells -- Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection -- The relationship of early studies of monoamine oxidase to present concepts -- Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson’s disease induced by the Japanese encephalitis virus -- Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl -- Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine -- Neuroprotection for Parkinson’s disease -- Marker for a preclinical diagnosis of Parkinson’s disease as a basis for neuroprotection -- Assessing neuroprotection in Parkinson’s disease: from the animal models to molecular neuroimaging in vivo -- Deprenyl: from chemical synthesis to neuroprotection -- The use of rasagiline in Parkinson’s disease -- Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases -- Acute and chronic effects of developmental iron deficiency on mRNA expression patterns in the brain -- Long lasting effects of infancy iron deficiency — Preliminary results -- Altered regulation of iron transport and storage in Parkinson’s disease -- Iron dyshomeostasis in Parkinson’s disease -- Cerebral oligemia and iron influence in cerebral structures — element of Morbus Parkinson Models? -- Impact of selenium, iron, copper and zinc in on/off Parkinson’s patients on L-dopa therapy -- Metal specificity of an iron-responsive element in Alzheimer’s APP mRNA 5?untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator -- Green tea catechins as brain-permeable, non toxic iron chelators to “iron out iron” from the brain.
520 _aThis book deals with basic and clinical aspects of monoamine oxidase (MAO) subtypes A and B highlighting its importance in neurological and psychiatric diseases. Consequently the therapeutic actions of MAO-A and -B inhibitors in Parkinson’s disease (PK) and depression are the focus of several chapters. As MAO is the basis of the development of the "oxidative stress hypothesis" of PD, several chapters are devoted to iron and iron-induced oxidative stress in various experimental studies and clinical conditions. Based on these findings, new compounds have been developed which not only block MAO, but are in addition, either inhibitors of acetylcholine esterase or have iron chelating properties. The aspect of "preclinical" and "clinical" neuro protection as well as MAO neuroprotection are additional topics covered in this book. MAO, iron and neuroprotection are seen in the framework of general anti Parkinson’s therapy with chapters on levodopa, dopaminergic receptor agonists and clinical issues.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700 1 _aRiederer, P.
_eeditor.
_9325529
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9783211333273
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-211-33328-0
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c293156
_d293156